Although MM patients with high risk scores were more sensitivity to bortezomib, it is essential to combine other therapies (such as lenalidomide, CD38 antibody, CAR-T cell etc.)to prolong progression-free survival. The gene discussed is CD38; the disease is Miyoshi myopathy.